Germany’s decisive vote late last year ended the deadlock over whether to renew the license for the world’s most commonly used weed killer, glyphosate – though...
When we talk about 'Big Data', what we mean is a massive collection of small data. In this case, it’s data garnered from individuals and used...
The report on the application of penalties for those involved in the production and circulation of falsified medicines published on 26 January shows a wide variation...
In these fast-changing times, with ageing populations and stunning breakthroughs in genomics, are we failing to ask the right questions in health care while making patients’...
Mark Lawler is a man of many talents. He’s a professor and cancer genomics expert at Queen’s University Belfast (QUB), an award-winning researcher, a scientific writer,...
The European Commission is launching today (23 January) a public consultation on the transparency and the independence of risk assessments and scientific studies as a follow-up...
Just imagine if the EU fell apart due to an inequality of access to the best medicines. It’s not as impossible as it may first sound,...